GlassScriptPhysician profile
Peter W Carter
NPI 1265428676
$9,945.01
in general payments reported to CMS, 2019-2025
65 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $238 · 2021: $127 · 2022: $1,998 · 2023: $2,253 · 2024: $1,661 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,545 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,545.32 |
| Education | $206.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $906.62 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $810.20 | 2019-2025 | Darzalex, Carvykti, Tecvayli |
| Merck Sharp & Dohme LLC | $664.56 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pfizer INC. | $595.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $480.04 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Gilead Sciences, INC. | $442.49 | 2021-2025 | Trodelvy |
| Eisai INC. | $423.57 | 2019-2025 | |
| Lilly USA, LLC | $378.00 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $344.75 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $333.61 | 2019-2025 | Ninlaro, Iclusig |
| Novartis Pharmaceuticals Corporation | $322.30 | 2019-2024 | |
| Abbvie INC. | $308.26 | 2019-2025 | Venclexta |
| Genzyme Corporation | $288.85 | 2020-2025 | |
| Celgene Corporation | $267.06 | 2022-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $260.23 | 2020-2025 | Enhertu, Injectafer |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $182.46 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Genentech USA, INC. | $182.11 | 2019-2024 | Polivy, Columvi, Tecentriq |
| Amgen INC. | $180.63 | 2019-2023 | Kyprolis, Blincyto |
| Puma Biotechnology, INC. | $164.68 | 2019-2023 | |
| Rigel Pharmaceuticals, INC. | $127.14 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacyclics LLC, An Abbvie Company | $125.43 | 2022-2023 | Imbruvica |
| Tesaro, INC. | $123.79 | 2019 | |
| Astellas Pharma US INC | $114.57 | 2022-2024 | Xospata, Padcev |
| Pharmacosmos Therapeutics INC. | $100.27 | 2023-2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $98.66 | 2022-2023 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $92.23 | 2019-2025 | |
| Sirtex Medical INC | $86.16 | 2022 | |
| Coherus Oncology, INC. | $83.63 | 2022-2025 | Loqtorzi |
| Kite Pharma, INC. | $83.48 | 2022-2025 | Yescarta |
| Beigene USA, INC. | $78.37 | 2023-2024 | Brukinsa |
| Tempus Ai, INC | $69.92 | 2024 | Xt Cdx |
| Mirati Therapeutics, INC. | $66.23 | 2023-2024 | Krazati |
| Janssen Pharmaceuticals, INC | $61.64 | 2019-2023 | Xarelto |
| Morphosys, US INC. | $56.14 | 2022-2024 | Monjuvi |
| Adc Therapeutics America, INC. | $54.23 | 2023-2024 | |
| Stemline Therapeutics INC. | $54.20 | 2023-2025 | Orserdu |
| Springworks Therapeutics, INC. | $52.18 | 2024-2025 | Ogsiveo, Gomekli |
| Jazz Pharmaceuticals INC. | $49.42 | 2023-2024 | |
| Kyowa Kirin, INC. | $48.78 | 2023-2025 | Poteligeo |
| Taiho Oncology, INC. | $48.60 | 2019-2023 | |
| Secura Bio, INC. | $46.96 | 2022 | |
| Emd Serono, INC. | $42.80 | 2022-2025 | Bavencio |
| Exelixis INC. | $41.83 | 2019 | |
| Seagen INC. | $41.02 | 2022-2023 | Tukysa |
| Cti Biopharma Corp. | $39.19 | 2023 | Vonjo |
| Karyopharm Therapeutics INC. | $39.13 | 2022-2023 | Xpovio |
| Genmab U.S., INC. | $38.34 | 2025 | Epkinly |
| Sobi, INC | $36.31 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $35.80 | 2023-2024 | Odomzo, Yonsa |
| Portola Pharmaceuticals, LLC | $33.03 | 2019 | |
| Aveo Pharmaceuticals, INC. | $32.81 | 2022-2023 | Fotivda |
| Novocure INC. | $29.72 | 2025 | Optune Lua (Novottf-200t) |
| Foundation Medicine, INC. | $27.11 | 2020-2022 | |
| Agios Pharmaceuticals, INC. | $25.93 | 2019-2020 | |
| Myovant Sciences INC. | $24.20 | 2022 | |
| Immunogen, INC. | $23.14 | 2024 | Elahere |
| Nestle Healthcare Nutrition INC. | $23.04 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.02 | 2019 | |
| Aimmune Therapeutics, INC. | $20.66 | 2024 | |
| Pharmaessentia USA Corporation | $20.40 | 2024 | Besremi |
| Medtronic USA, INC. | $19.64 | 2019 | |
| Biocompatibles, INC. | $19.42 | 2019 | |
| Sumitomo Pharma America, INC. | $19.10 | 2023 | Orgovyx |
| Teva Pharmaceuticals USA, INC. | $16.59 | 2019 | |
| Array Biopharma INC | $16.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.